Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

NCT07423572 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhejiang Chinese Medical University as lead sponsor.

NCT NCT07423572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07423572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)
Lead sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
September 28, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory idiopathic membranous nephropathy